According to our recent payer coverage analysis for Parkinson’s disease treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for Parkinson’s disease treatments shows that under the pharmacy benefit, about 36% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: In May 2020, the FDA approved Sunovion Pharmaceuticals Inc.’s Kynmobi (apomorphine) for the acute, intermittent treatment of “off” episodes in people with Parkinson’s disease.